{"id":62414,"date":"2025-12-29T16:05:56","date_gmt":"2025-12-29T15:05:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/"},"modified":"2025-12-29T16:05:56","modified_gmt":"2025-12-29T15:05:56","slug":"immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/","title":{"rendered":"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d"},"content":{"rendered":"
\n

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX<\/a>), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of \u201cThe 100 Most Influential People in Oncology in 2025.\u201d Soon-Shiong is the company\u2019s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing the goal of a cancer-free society.<\/p>\n

<\/a>
<\/a><\/p>\n

\nOn its website<\/a> announcing the honor, OncoDaily highlighted Soon-Shiong\u2019s extensive scientific and research accomplishments, noting that The 100 Most Influential People in Oncology<\/i> in 2025 recognizes changemakers in cancer care who have helped shape current oncology practice and continue to drive innovation across research, patient outcomes, advocacy, philanthropy, leadership, and education.<\/p>\n

\nOncoDaily, the \u201cVoice of Oncology,\u201d is a respected global source of news and information about developments in oncology, whose editorial staff and advisory board is comprised of leading academics, researchers and physicians specializing in cancer. Its annual Influential People list highlights individuals whose work is shaping oncology through clinical leadership, scientific innovation, education, advocacy, and philanthropy.<\/p>\n

\n\u201cDr. Soon-Shiong has earned this honor in recognition of his lifelong commitment to science, medicine, and patient care, a commitment that inspires our team and our partners every day,\u201d said Richard Adcock, President and CEO of ImmunityBio. \u201cHis ideas and leadership are a driving force powering our mission to bring transformative therapies to people living with cancer and other serious diseases.\u201d<\/p>\n

\nAbout ImmunityBio<\/b><\/p>\n

\nImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company\u2019s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit ImmunityBio.com<\/b><\/a> (Founder\u2019s Vision) and connect with us on X<\/b><\/a> (Twitter), Facebook<\/b><\/a>, LinkedIn<\/b><\/a>, and Instagram<\/b><\/a>.<\/p>\n

\nForward Looking Statements<\/b><\/p>\n

\nThis communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements, if any, regarding the potential implications of the recognition of Dr. Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. by OncoDaily as one of the most influential people in oncology in 2025. Forward-looking statements are based on management\u2019s current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company\u2019s control, that could cause actual outcomes or results to differ materially from those expressed or implied by these statements. These risks and uncertainties include, but are not limited to, changes in business, regulatory, scientific, or market conditions. More details about these and other risks that may impact ImmunityBio\u2019s business are described under the heading \u201cRisk Factors\u201d in the Company\u2019s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company\u2019s Form 10-Q filed with the SEC on November 5, 2025 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC\u2019s website at www.sec.gov<\/a>. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors
\n
<\/b>Hemanth Ramaprakash, PhD, MBA
\n
<\/b>ImmunityBio, Inc.
\n
<\/b>+1 858-746-9289
\n
Hemanth.Ramaprakash@ImmunityBio.com<\/a><\/p>\n

\nMedia
\n
<\/b>Sarah Singleton
\n
<\/b>ImmunityBio, Inc.
\n
<\/b>+1 415-290-8045
\n
Sarah.Singleton@ImmunityBio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of \u201cThe 100 Most Influential People in Oncology in 2025.\u201d Soon-Shiong is the company\u2019s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62414","6":"format-standard","7":"category-industry"},"yoast_head":"\nImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of \u201cThe 100 Most Influential People in Oncology in 2025.\u201d Soon-Shiong is the company\u2019s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T15:05:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251229462120\/en\/1463552\/22\/BusinessWire_ImmunityBio.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d\",\"datePublished\":\"2025-12-29T15:05:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/\"},\"wordCount\":693,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251229462120\\\/en\\\/1463552\\\/22\\\/BusinessWire_ImmunityBio.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/\",\"name\":\"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251229462120\\\/en\\\/1463552\\\/22\\\/BusinessWire_ImmunityBio.jpg\",\"datePublished\":\"2025-12-29T15:05:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251229462120\\\/en\\\/1463552\\\/22\\\/BusinessWire_ImmunityBio.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251229462120\\\/en\\\/1463552\\\/22\\\/BusinessWire_ImmunityBio.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/","og_locale":"en_US","og_type":"article","og_title":"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d - Pharma Trend","og_description":"CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of \u201cThe 100 Most Influential People in Oncology in 2025.\u201d Soon-Shiong is the company\u2019s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-29T15:05:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251229462120\/en\/1463552\/22\/BusinessWire_ImmunityBio.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d","datePublished":"2025-12-29T15:05:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/"},"wordCount":693,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251229462120\/en\/1463552\/22\/BusinessWire_ImmunityBio.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/","url":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/","name":"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251229462120\/en\/1463552\/22\/BusinessWire_ImmunityBio.jpg","datePublished":"2025-12-29T15:05:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251229462120\/en\/1463552\/22\/BusinessWire_ImmunityBio.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251229462120\/en\/1463552\/22\/BusinessWire_ImmunityBio.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immunitybio-founder-dr-patrick-soon-shiong-recognized-as-one-of-100-most-influential-people-in-oncology-in-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62414"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62414\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}